Merck & Co mauled as forecasts fall short

30 July 2024

Shares in Merck & Co (NYSE: MRK) were more than 10% lower during Tuesday’s early trading in New York after the US pharma giant announced its second-quarter financial results and latest guidance for 2024.

Worldwide sales hit $16.11 billion, up 7% year-over-year and ahead of analysts’ expectations. Merck's adjusted earnings reversed from a year-earlier loss to $2.28 per share, beating Wall Street's forecast for $2.16.

For the year, the company narrowed its sales outlook and now expects $63.4 billion to $64.4 billion. Merck also cut its adjusted earnings outlook $0.60 at the midpoint, to $7.94 to $8.04 per share. Analysts were expecting earnings of $8.16 a share and sales of $64.29 billion, with Merck’s more pessimistic view perhaps explaining the stock market reaction.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK